Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Swing-Mesh™ Study (SMS) is a clinical trial aimed at evaluating a new type of mesh implant called Swing-Mesh™ for repairing inguinal hernias. This study is looking at how safe and effective this lightweight mesh is compared to standard options when used in minimally invasive surgeries. If you're an adult over 18 years old and are scheduled for elective surgery to fix a groin hernia, you might be eligible to participate in this trial. Both men and women can join, as long as they meet certain health criteria and give their written consent.
Participants in the trial will receive the Swing-Mesh™ implant during their surgery and will be monitored for up to six months to see how well it works. The main focus is to check if the hernia comes back after surgery. Additionally, the study will look at any pain or discomfort participants may experience, as well as any complications that could arise. This trial is currently recruiting participants, so if you or someone you know is considering hernia repair, this could be an opportunity to contribute to important research while receiving care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • elective groin hernia repair
- • age \> 18 years
- • male and female patients can participate
- • eligibility for laparoendoscopic repair
- • signed written informed consent
- Exclusion Criteria:
- • age \<18 years
- • emergency surgery (incarcerated hernia)
- • contaminated surgical field
- • recurrent hernia
- • extremely large scrotal hernias with the need of other abdominal compartment syndrome (ACS) preventive procedures (botulin injection, bowel resection, preoperative progressive pneumoperitoneum - PPP)
- • M3 or M3+L1-3 (EHS classification) groin hernia confirmed during surgery
About Swissmed Hospital
Swissmed Hospital is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. Renowned for its state-of-the-art facilities and multidisciplinary approach, the hospital fosters collaboration among healthcare professionals, researchers, and patients to develop cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, Swissmed Hospital aims to contribute significantly to the scientific community and improve health outcomes through rigorous clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gdańsk, , Poland
Patients applied
Trial Officials
Mateusz Zamkowski, MD, PhD
Study Chair
Swissmed Hospital
Maciej Śmietański, prof.
Study Director
Swissmed Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported